We’re the leading resource for those affected by bleeding disorders. You can count on our organization to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.
Our programs are designed to provide relevant information to support people with bleeding disorders and their families with their ability to make informed choices.
Take a look.
Fundraisers and events help us raise awareness and generate crucial resources in support of the bleeding disorders community. Join us at our next event and see how you can get involved. Find something to do.
Our grassroots network is an integral part of our larger community. Team up with us and see what a huge difference a little bit of your time can make.
News & Events
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved Hemlibra® for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors (FVIII). The therapy, which was co-developed by Genentech, Chugai and Roche, was already FDA approved in the fall of 2017 for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with FVIII inhibitors.
The National Hemophilia Foundation (NHF) is pleased to announce the 2018 NHF-Shire Clinical Fellowship award recipients: Hanny Al-Samkari, MD, of Boston Hemophilia Center/Massachusetts General Hospital and Harvard University, and Michael H. White, MD, of Emory University and Children’s Healthcare of Atlanta (CHOA).
Fall is upon us as crisper, cooler weather prevails across much of the country. It is arguably the season most evocative of change, and in that spirit NHF’s information resource center HANDI would like to share several resources that may offer guidance as you or a family member face a major life transition.
HANDI hopes that you find these resources to be helpful and informative!
Watch this video to learn how Copay accumulator adjustments affect patients requiring specialty medications with no generic alternatives.
The National Heart, Lung, and Blood Institute (NHLBI) is currently seeking public feedback that will inform future research the agency will conduct on inhibitors to factor VIII (FVIII) in patients with hemophilia A. To this end, the NHLBI has released a Request for Information (RFI) to solicit perspectives and comments from the bleeding disorders community on potential strategies, scientific opportunities and priorities, and the requisite infrastructure to optimize inhibitor research.